“For adults aged 50 years or older, an investigational messenger RNA (mRNA)-based vaccine (mRNA-1010) is superior to standard-dose licensed vaccines for preventing influenza-like illness, according to a study published in the New England Journal of Medicine…

Overall, 20,350 participants received mRNA-1010 and 20,353 received the standard-dose comparator. The researchers found that 2.0% and 2.8% of the recipients of mRNA-1010 and the standard-dose comparator, respectively, had RT-PCR-confirmed, protocol-defined influenza-like illness, corresponding to a relative vaccine efficacy of 26.6% and meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions occurred more often with mRNA-1010 than the standard-dose comparator; they were mainly mild-to-moderate and transient. Overall, 2.2% and 1.9% of recipients of mRNA-1010 and the standard-dose comparator, respectively, had serious adverse events.”

From Medical Xpress.